Close Menu

For the Rest

Johnson & Johnson bid 1.75 billion euros to buy the rest of the Dutch biotechnology company Crucell, reports The New York Times' DealBook, which notes that Johnson & Johnson already owns nearly 18 percent of the biotech. The offer for the company, which specializes in vaccines and therapeutics for infectious diseases, is 24.75 euros a share, and is supported by the Crucell board. The bid goes to a vote in early February.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

23andMe has launched a new tool that estimates someone's risk of developing severe COVID-19 if infected, Bloomberg reports.

The Guardian reports that Pasteur Institute researchers are halting their development of a SARS-CoV-2 vaccine following disappointing initial results.

The Wall Street Journal reports that an increased number of younger patients have been hospitalized as the new SARS-CoV-2 strain spread across the UK.

In Cell this week: proteomic patterns among COVID-19 affected tissue samples, transcriptome atlas of developing intestines, and more.